

International Journal for Pharmaceutical Research Scholars (IJPRS)



ISSN No: 2277 - 7873

RESEARCH ARTICLE

Simultaneous Estimation of Metformin HCl and Gliclazide by Q- Analysis Method Chopade JR*¹, Deshpande SV¹, Shah S¹

* ¹Department of Pharmaceutical Chemistry, Pad. Dr. D. Y. Patil college of Pharmacy, Akurdi, Pune. Manuscript No: IJPRS/V2/I3/00128, Received On: 27/07/2013, Accepted On: 08/08/2013

ABSTRACT

Q- Analysis method for simultaneous estimation of Metformin HCl and Gliclazide in tablet dosage form have been developed. The method was simple, precise, accurate, reproducible and economical. Linearity was observed in the concentration range of 2-12 μ g/ml for GLZ and 2-12 μ g/ml for MET. The result of analysis have been validated as per ICH Guidelines.

KEYWORDS

Gliclazide, Metformin hydrochloride, λmax , Q- Analysis method.

INTRODUCTION

Gliclazide(GLZ), a sulphonyl urea derivative is used as an oral hypoglycemic agent. Chemically it is 1-(3-azabicyclo [3.3.0] oct-3-yl)-3pmethylpheylsulphonylurea.

It is official in British Pharmacopoeia 2007. Metformin Hydrochloride (MET) is 3-(diaminomethylidene)-1, 1-dimethylguanidine. It is an oral anti-diabetic drug which is the first line drug of choice for the treatment of type 2 diabetes, particularly in overweight or obese people and those with normal kidney function. It is an oral anti-diabetic drug from the biguanide class. It is the first-line drug for the treatment of type 2 diabetes, particularly in overweight and obese people and those with normal kidney function and evidence suggests it may be the best choice for people with heart failure.

The combination of GLZ and MET is used in non insulin dependent diabetes mellitus. Non aqueous method have been reported for analysis of gliclazide in B.P. and metformin hydrochloride in I.P.

*Address for Correspondence: Jyotsna Chopade Department of Pharmaceutical chemistry, Pad. Dr. D. Y. Patil college of Pharmacy, Akurdi, Pune, India. E-Mail Id: jyotsnachopade@ymail.com Several HPLC methods have been developed for gliclazide and metformin hydrochloride in plasma. Literature survey revealed that Q-Analysis method is not developed for estimation of gliclazide and metformin hydrochloride in combine dosage forms Simultaneous UV spectrophotometric methods have been reported for estimation of gliclazide and metformin hydrochloride in combine dosage forms. Hence, an attempt has been made to develop new Q-Analysis UV method for its estimation in pharmaceutical dosage formulations with good accuracy, simplicity and sensitivity.



MATERIALS AND METHODS

Instrument

Shimadzu UV-1700 UV/VIS Spectrophotometer was used with 1 cm matches quartz cell.

Materials

Gift samples of MET and GLZ were procured from Emcure Pharmaceutical LTD, Pune. Tablets containing both drugs i.e. Metformin Hydrochloride and Gliclazide were purchased from local pharmacy of commercial brand Glizid-M (Panacea biotech)

Absorbance ratio (Q Analysis) U.V. spectrophotometric method

Apparatus

A Shimadzu UV-1700 UV/VIS spectrophotometer with UV Winlab Software was used. Sartorius ADD-BL-02 balance was used. Calibrated glasswares were used for the study. Trans-o-sonic ultrasonicator, 0.45 μ filter papers (PVDF/Nylon filters) also used.

Selection of Solvent

Water was selected as the solvent for dissolving Metformin Hydrochloride and Gliclazide.

Preparation of Standard Solutions

In order to prepare stock solution, 10 mg Metformin hydrochloride and 10 mg Gliclazide were accurately weighed in two separate volumetric flasks, dissolved in water and diluted to 100 ml with the water. Standard solution was prepared by further diluting 1 ml stock solution with 10 ml water to obtain 10 μ g/ml concentration of Metformin hydrochloride and 10 μ g/ml concentration of Gliclazide.

Determination of λmax

Both the standard solutions were scanned separately between 400 nm to 200nm. The overlain spectrum of both drugs was recorded, Fig. 1; from the overlain spectrum, two wavelengths 233 nm (λ max of Metformin hydrochloride) and 229 nm (Isoabsorptive point) were selected for estimation of drugs using absorbance ratio method.

Study of Beer-Lambert's Law

Aliquots of standard stock solution of Metformin Hydrochloride and Gliclazide were diluted in a series of 100 ml flasks with water to get concentration in range of 2-12 μ g/ml for

Metformin hydrochloride and 2-12 μ g/ml for Gliclazide. Similarly aliquots of mixed standard stock solution were diluted in a series of 100 ml flasks with water to get concentration in range of 2-12 μ g/ml for Metformin hydrochloride and 2-12 μ g/ml for Gliclazide. Absorbances of each of the resulting solutions were measured at 233 nm and 229 nm in 1.0 cm cell using solvent blank.



Figure 1: Overlein spectrum of Metformin HCl and Gliclazide

Determination of Absorptivity Value at Selected Wavelength

For Metformin hydrochloride

An accurately weighed quantity of Metformin hydrochloride (10mg) was transferred in 100 ml volumetric flask, dissolved in water, then dilute upto mark with water (concentration of stock solution: 100 μ g/ml). 1 ml of above stock solution further diluted to 10 ml with water to form final standard solution 10 μ g/ml)

For Gliclazide

An accurately weighed quantity of Gliclazide(10mg) was transferred in 100 ml volumetric flask, dissolved in water, then dilute upto mark with water (concentration of stock solution: 100 μ g/ml). 1 ml of above stock solution further diluted to 10 ml with water to form final standard solution 10 μ g/ml). The absorbance of each of the above solutions were measured in triplicate in 1.0 cm cell against solvent blank at 233 nm, 229 nm and A (1%,

1cm) values were calculated using formula as given below.

A (1%, 1cm) = Absorbance / Concentration (g/100ml)

The results are shown in Table. 1a, 1b.

Table 1a: A (1%, 1cm) va	lues of Metformin
HCl at 229 and	233 nm

Sr. No.	Mean A (1%, Metformi	an A (1%, 1 cm) for Metformin HCl		
	229 nm	233 nm		
1	1017	953		
2	2 1013 954			
3	1013	953		
4	1014	953		
5	1016	954		
Mean ± S. D.	1014.6 ± 1.816	953.4 ± 0.547		

Table 1b: A (1%, 1cm) values of Gliclazide at 229 and 233 nm

Sr. No.	Mean A (1%, 1 cm) for Gliclazide			
	229 nm	233 nm		
1	388	219		
2	387	218		
3	387	218		
4	386	217		
5	5 387 218			
Mean ± S. D.	387 ± 0.707	218.0 ± 0.707		

Application of Proposed Method for Estimation in Standard Laboratory Mixture

An accurately weighed quantity of Metformin hydrochloride (10 mg) and Gliclazide(10 mg) were transferred to a 100 ml volumetric flask, sufficient quantity of water was added, shaken and dilute upto mark with water. Further 1 ml portion of above stock solution was diluted to 10 ml with water. The absorbance of resulting solution was measured at 233 nm and 229 nm in 1.0 cm cell using water as blank. The contents of Metformin Hydrochloride and Gliclazide were calculated by substituting values in the formulae given below:

For estimation of MET For estimation of FNB

Qm-Qy	А	Qm-Qx	А
Cx =	x	Cy = x	
Qx-Qy	ax	Qy-Qx	ay

Where,

Cx = Concentration of Metformin hydrochloride in g/100ml

Cy = Concentration of Gliclazidein in g/100ml

Qm =Ratio of absorbance of laboratory mixture at 233 nm and 229 nm

Qx = Ratio of absorptivity of Metformin hydrochloride at 233 nm and 229 nm

ax = Absorptivity of Metformin hydrochloride

ay = Absorptivity of Gliclazide

A = Absorbance of mixture at Isoabsorptive point.

Amount of drug estimated = $C \times D \times V$

Where,

C = Cx or Cy = Concentration of MET or GLI (mg/ml)

D = Dilution factor = 10

V = Volume of stock solution = 100 ml

From the amount estimated by above method, percentage estimation was calculated by using formula.

Amount of drug estimated

% Estimation = ----- x 100

Weight of drug taken

The results of laboratory mixture study are shown in Table 2.

Table 2: Analysis of Metformin HCl and Gliclazide in standard laboratory mixture

Sr no	Metformi n estimated	Gliclazid e estimated	% Estimation Metformin	% Estimation Gliclazide
1	10.12	10.04	101.2	100.4
2	10.05	9.99	100.5	99.9
3	10.15	10.01	101.5	100.1
4	10.18	10.05	101.8	100.5
5	10.16	10.03	101.6	100.3
Mean ± SD		101.32 ± 0.506	100.24 ± 0.240	
% RSD		0.5003470 9	0.24025	

Application of Proposed Method for Estimation of MET and GLI in Tablet Dosage Forms

Sample preparation: 20 tablets were weighed and powdered, quantity of sample powder containing equivalent to 500 mg of MET and 80 mg of GLI was transferred to 200 ml volumetric flask, sufficient quantity of water was added, and sonicated for 15 minutes and diluted upto mark with water. Filtered through 0.45μ membrane filter paper. A 2 ml of filtrate was further diluted to 100 ml with water to get final concentration of about 50 µg/ml MET and 8 µg/ml GLI. The absorbance of resulting solutions was measured at 233 nm and 229 nm in 1.0 cm cell using solvent blank. The results were calculated by using the same formula as described under estimation of standard laboratory mixture. Further % labeled claim was determined using the formula.

% labeled = -----x 100 claim

Weight taken x Label claim

The results of estimation in marketed formulation are shown in Table 3.

Accuracy Study

It was done by recovery study. Sample solutions were prepared by spiking at about 80 %, 100 % and 120 % of specification limit to Placebo and analyzed by the proposed method. % Recovery was determined using the formula.

Amount found

Percentage Recovery = ------ x 100

Actual amount added

Amount added x potency

Actual amt. added (mg) =-----

100

Results are shown in Table 4.

Method Validation

Accuracy

Accuracy of the proposed method was ascertained on the basis of recovery studies. Results are shown in Table 4.

Precision

Precision of any analytical method is expressed as SD and RSD of series of measurements. Precision of the method was studied as intra-day and inter-day variations. 20 tablets were weighed and powdered, quantity of sample powder containing equivalent to 500 mg of MET (and 80 mg of GLI) was transferred to 200 ml volumetric flask, sufficient quantity of water was added, and sonicated for 15 minutes and diluted upto mark with water.

Sr. No.	Sample taken in mg	Metformin HCl mg/tab	Gliclazide mg/tab	% Estimation of Metformin HCl	% Estimation of Gliclazide
1	650.81	500.21	80.12	100.04	100.15
2	650.89	499.94	79.89	99.988	99.86
3	651.21	499.98	80.21	99.996	100.26
4	651.12	500.12	79.98	100.024	99.97
5	650.88	499.12	79.96	99.824	99.95
	Mean ± S.	.D.		99.9744 ± 0.087	100.038 ± 0.163
	% RSD			0.0866755	0.162634

Table 3: Analysis of Metformin HCl and Gliclazide in commercial formulation

Table 4: Standard Addition Technique for determination of Metformin HCl and Gliclazide using Absorption ratio method (n=3)

Compound (mg)	Amount added (%)	Total amount (mg)	Amount found (mg)	Recovery (%)	Average (%)
	80	900	896.5 ± 0.508	$99.61{\pm}0.05$	
Metformin (500)	100	1000	995.9 ± 0.611	99.59 ± 0.10	99.39
()	120	1100	1091.4 ± 0.519	99.21 ± 0.28	
	80	144	145.12 ± 0.810	100.77 ± 0.03	
Gliclazide	100	160	159.96 ± 0.558	99.98 ± 0.04	99.68
(00)	120	176	175.98 ± 0.673	$99.99{\pm}0.08$	

Table 5: Precision studies of proposed absorption ratio method

Drug	Conc. µg/ml	Intraday Found Conc. ± SD	RSD (%)	Interday Found Conc. ± SD	RSD (%)
Metformin		39.87 ± 0.082	0.438	39.89 ± 0.098	0.299
HCl	50	59.86 ± 0.016	0.027	59.82 ± 0.024	0.190
		79.91 ± 0.029	0.036	80.01 ± 0.028	0.082
		39.89 ± 0.043	0.108	39.99 ± 0.045	0.245
Gliclazide	08	60.07 ± 0.045	0.075	60.04 ± 0.049	0.082
		80.07 ± 0.025	0.031	80.03 ± 0.029	0.036

Filtered through 0.45 μ membrane filter paper. A 2 ml of filtrate was further diluted to 100 ml with water to get final concentration of about 50 μ g/ml MET and 8 μ g/ml GLI. The absorbance of final the solution was measured after 0 hr, 3hr and 6hr in 1.0 cm cell at 229 nm and 233 nm. Similarly the absorbance of the same solution was measured on day 1st, 3rd and 5th and the percent assay was calculated using formulae as described under marketed formulation.

The results are shown in Table.5.

Linearity and Range

Accurately weighed quantities of tablet content equivalent to 80% to 120% of label claim of MET and GLI were taken and dilutions were made as described under marketed formulation. The absorbance of resulting solution was measured at 233 nm and 229 nm in 1.0 cm cell using solvent blank. The graphs was constructed as % label claim versus absorbance plot and found to be linear as depicted in Fig.2, 3.



Figure 2: Calibration curve for Metformin Hydrochloride



Figure 3: Calibration curve for Gliclazide

Ruggedness

Ruggedness of the proposed method was determined by analyzing aliquots from homogeneous slot by two analyst using same operational and environmental conditions; the results are shown in Table.6.

Table 6: Ruggedness stuc	ly
--------------------------	----

Analyst 1	Metformin HCl	Gliclazide			
Mean(%Ass ay)±SD	99.98 ± 0.087	$\begin{array}{c} 100.040 \pm \\ 0.163 \end{array}$			
% R.S.D	0.090	0.16			
Stu	Study by ANALYST 2				
Analyst 2	Metformin HCl	Gliclazide			
Mean (%Assay) ± SD	99.98 ± 0.087	100.040 ± 0.163			
% R.S.D	0.090	0.16			

RESULT AND DISCUSSION

Metformin Hydrochloride and Gliclazide. indicated for the treatment of non-insulin dependent type II diabetes mellitus. Literature scan revealed no absorbance ratio UV spectrophotometric method was developed for the determination of Metformin Hydrochloride and Gliclazide. Fig 1 shows typical overlain spectrum of Metformin Hydrochloride and Gliclazide. The linearity of method was statistically confirmed. The correlation coefficients (r) for calibration curves were not less than 0.99. The relative standard deviation values of the slope were not more than 2%. The analytical recovery at three different concentrations of Metformin Hydrochloride and Gliclazide was determined. In absorbance ratio method, 233 nm which was λ max of Metformin Hydrochloride and 229 nm which was isoabsorptive point, were selected for analysis. Absorbance ratio UV spectrophotometric method was validated. Therefore proposed validated method was successfully applied to determine Metformin Hydrochloride and Gliclazide in tablet dosage form.

CONCLUSION

Absorption Ratio method was developed and validated as per ICH guidelines for estimation of Metformin HCl and Gliclazide. This method was applied for estimation of these compounds in the marketed formulation. The method has been evaluated for the linearity, accuracy, precision and Robustness in order to ascertain the suitability of the method. It has been proved that the developed method was linear in the concentration range of 2-12 ug/ml.

High percentage recovery showed that method was free from interference of excipients used in the formulations. The results of the study indicates that the proposed absorbance ratio UV spectrophotometric method of analysis can be used in quality control departments with respect to routine analysis for the assay of the tablets containing Metformin Hydrochloride and Gliclazide.

REFERENCES

- 1. Watson GD, "Pharmaceutical Analysis. Elsevier Churchill Livingstone", Second edition, 2005.
- 2. Christian Gary D, "Analytical chemistry", Jhon wiley & sons, Sixth edition, 2004.
- 3. Skoog, Holler, Crouch, "Fundamentals of Analytical Chemistry", Indian edition, Saurabh Printers, 2006.
- 4. Beckett AH, Stenlake JB, "Practical Pharmaceutical chemistry", CBS Publishers distributors Fourth edition, part-2, 2002, 275.
- 5. Kalsi PS, Spectroscopy of Organic Compounds. New age international Publishers, Sixth edition, New Delhi.
- 6. Sharma YR, In introduction of organic spectroscopy. CBS Publisher and

Distributors, Fourth edition, New Delhi, 1991.

- ICH, Q2A, Validation of Analytical Procedure: Methodology, International Conference on Harmonization, Geneva, October, 1994.
- ICH, Q2B Validation of Analytical Procedure: Methodology, International Conference on Harmonization, Geneva, March, 1996.
- 9. ICH Guidance on Analytical Method Validation, International Convention on Quality for the Pharmaceutical Industry, Toronto, Canada, September 2002.
- 10. The Merck index: Merck research laboratories, Thirteenth edition, white house, 2001, 10089.
- 11. Tripathi KD: Essentials of Medical Pharmacology. Jaypee Bros. Medical Publishers, New Delhi, Edition 7, 2008: 266
- 12. Chaudhary J. Jain А, Saini V. "Simultaneous estimation of multicomponent UVformulation by VISIBLE Spectroscopy: An overview", International Research journal of Pharmacy, 2011, 2(12), 81-83.
- 13. Patel NB, Aravdiya AC, Desai HT, "Development and validation of two spectrophotometric method for simultaneous estimation of Metronidazole and Ofloxacin in Suspension", International Journal of Pharmaceutical Sciences and Research 2011, 2(12), 3202-3206.
- 14. Jamadar Samina A. Mulye, Snehal P, Karekar Poonam S, Pore Yogesh V. Burade., Kishor B, "Development and Validation of UV spectrophotometric method for the determination of Gliclazide in tablet dosage form", Scholars Research Library, Der Pharma Chemica, 2011, 3 (4), 338-343.
- Loni AB, Ghante MR, Sawant SD, "Simultaneous UV Spectrophotometric Method for Estimation of Sitagliptin phosphate and Metformin hydrochloride in

Bulk and Tablet Dosage Form", Scholars Research Library, Der Pharma Chemica, 2012, 4 (3), 854-859.

- 16. Bhaskar R, Bhaskar R, Sagar MK, Saini V, "Multivariate Chemometric Assisted Analysis of Metformin Hydrochloride, Gliclazide and Pioglitazone Hydrochloride in Bulk Drug and Dosage Forms", Advanced Pharmaceutical Bulletin, 2013, 3(1), 79-84.
- 17. Dhabale PN, Seervi CR, "Simultaneous UV Spectrophotometric method for estimation of Gliclazide and Metformin Hydrochloride in tablet dosage form", International Journal of Chem Tech Research, 2010, 2 (2), 813-817.
- 18. Dadhania KP, Nadpara PA, Agrawal YK, "Development and validation of spectrophotometric method for simultaneous estimation of Gliclazide and metformin

hydrochloride in bulk and tablet dosage form by simultaneous equation method", International Journal of Pharmaceutical Sciences and Research, 2011, 2(6), 1559-1563.

- 19. Bhamare PC, Bari SB, Natarajan S, Patil AA, Patil SH, Shirode, PT, "A New Analytical Method Development and Validation of Metformin Hydrochloride and Fenofibrate by Absorbance Ratio UV Spectrophotometric Method", Asian Journal of Biochemical and Pharmaceutical Research, 2011, 2(1), 115-128.
- Sarangi RR, "Simultaneous UV-Spectrophotometric Estimation of Glipizide and Metformin in Bulk and Its Dosage Form", International Journal of Pharmaceutical & Biological Archives 2011, 1137-1145.